Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Guides for Patients: Disclaimer and declaration of interest

Disclaimer

ESMO Guides for Patients are prepared in collaboration with the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of their cancer type and understand the best treatment choices available. Please note that information in these Guides for Patients does not replace a medical consultation. ESMO recommends that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease.

Patient information based on the ESMO Clinical Practice Guidelines - Conflict of interest disclosures

  • Aglione Antonio: No conflicts of interest to declare
  • Aguarón Alfonso: No disclosure at time of going online
  • Allum William: No conflicts of interest to declare
  • Apostolidis Kathi: A volunteer cancer patient advocate and the Vice-President of ECPC, the European Cancer Patient Coalition. ECPC has received support to carry its action plan from AbbVie, Amgen, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly & Co, Gilead, Helsinn, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, and Roche.
  • Arnold Dirk: Research grants – Roche, Sanofi
  • Baccarani Michele: Honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad for participation to advisory boards and as a speaker at scientific and educational meetings.
  • Bayne Louise: No disclosure at time of going online
  • Beaumont Stéphane: No disclosure at time of going online
  • Beveridge Jane: No conflicts of interest to declare
  • Bjerrum Thisted Lise: No conflicts of interest to declare
  • Blay Jean-Yves: No conflicts of interest to declare
  • Boland Greet: No conflicts of interest to declare
  • Bolaños Natacha: No disclosure at time of going online
  • Bouche Gauthier: No conflicts of interest to declare
  • Bouguet Guy: No disclosure at time of going online
  • Bellmunt Joaquim: Consultant or Advisory Role - Lilly, Pierre Fabre and Sanofi Aventis
  • Billiau An: Medical writer of Celsus Medical Writing LLC. – Honoraria from Anticancer Fund
  • Bosman Patricia: No conflicts of interest to declare
  • Bramley Claire: Stock ownership: GSK
  • Brandt Juliane: Speaker’s honoraria: AbbVie, Nationale Gesundheitsakademie, Roche
  • Buske Christian: Research funds: Roche, Janssen; Speaker’s bureau: Roche, Janssen, Pfizer
  • Cardoso Fatima: Receipt of honoraria or consultation fees: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Seattle Genetics, Teva
  • Casali Paolo: Consultancy/Honoraria: Amgen Domplé, ARIAD, Bayer, GlaxoSmithKline, Infinity, Janssen Cilag, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Sanofi
  • Casanovas Taltavull Teresa: No disclosure at time of going online
  • Colia Vittoria: No conflicts of interest to declare
  • Colombo Nicoletta: Consulting and advisory services, speaking or writing engagements, public presentations: Roche, AstraZeneca, Pharma Mar, Tesaro (GSK), Clovis, Advaxis, Pfizer, Takeda, Immunogen, Biocad; Institutional support for clinical trials or contracted research: Roche, Pharma Mar and AstraZeneca
  • Cunningham David: Research funding - Roche and Amgen
  • Curigliano Giuseppe: Honoraria for speaker’s engagement: Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, Nanostring, Samsung, Celltrion, BMS, MSD; Honoraria for providing consultancy: Roche, Seattle Genetics, Nanostring; Honoraria for participating in Advisory Board: Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, Mylan; Honoraria for writing engagement: Novartis, BMS; Honoraria for participation in Ellipsis Scientific Affairs Group; Institutional research funding for conducting phase I and II clinical trials: Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, Medimmune
  • Curtis Christopher: No disclosure at time of going online
  • De Lorenzo Francesco: A volunteer cancer patient advocate and the President of ECPC, the European Cancer Patient Coalition. ECPC has received support to carry its action plan from AbbVie, Amgen, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly & Co, Gilead, Helsinn, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, and Roche.
  • Deschamps André: No disclosure at time of going online
  • Diamanti Orejeta: No conflicts of interest to declare
  • Douillard Jean-Yves: No conflicts of interest to declare
  • Dowling John: No disclosure at time of going online
  • Dreyling Martin: Advisory Board: Bayer, Celgene, Gilead, Janssen, Pfizer; Consultancy/Honorari: Celgene, Janssen, Mundipharma, Pfizer, Roche; Research funding to the institution: Celgene, Janssen, Pfizer, Mundipharma, Roche.
  • Dummer Reinhard: Research funding - Astra Zeneca, Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Bristol-Myers Squibb, Roche, GlaxoSmith Klein, Bayer; Consultant or Advisory Board: Astra Zeneca,Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Genta, Bayer, Roche, Bristol-Myers Squibb, GlaxoSmith Klein, Spirig.
  • Fenlon Deborah: No disclosure at time of going online
  • Fey Martin: No conflicts of interest to declare
  • Florindi Francesco: No conflicts of interest to declare
  • Fowler Matthew: No conflicts of interest to declare
  • Freitas Jorge: No conflicts of interest to declare
  • Geissler Jan: No disclosure at time of going online
  • Giles Rachel H.: Speakers’ Honoraria from Ipsen and Novartis. The IKCC receives project and educational funds from BMS, Ipsen, Exelixis, MSD, Pfizer, Novartis, Eisai, and Roche
  • Glimelius Bengt: No conflicts of interest to declare
  • Gonzato Ornella: No conflicts of interest to declare
  • Haanen John: Honoraria from Amgen, Merck, MSD, Helsinn, Tesaro and Hexaland; A member of the advisory board of Merck, MSD, Helsinn and Tesaro
  • Hewitt Julie: No conflicts of interest to declare
  • Horwich Alan: His institution is inventor of abiraterone and receives royalty payments; no personal conflicts.
  • Hotlet Rüsz Maria: No conflicts of interest to declare
  • Jerome Olivier: No disclosure at time of going online
  • Jewel Anna: No conflicts of interest to declare
  • Jezdic Svetlana: No conflicts of interest to declare
  • Jordan Karin: Personal financial interests, honoraria for speaker, consultancy or advisory role, royalties, direct research funding: MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, Pomme-med, Pharma Mar, Shire, ClinSolResearch, G1 Therapeutics, Annals of Oncology, UpToDate, Prime Oncology, medupdate, arttempi; Institutional financial interests: MSD, Helsinn, Riemser, Acacia, Menarini
  • Jost Lorenz: No conflicts of interest to declare
  • Ihlen Regine Deniel: Lung Cancer Europe (LuCE) is a non-profit organisation whose activities are funded by balanced support from BMS and MSD
  • Keilholz Ulrich: Honoraria: Amgen, BMS, GSK, Glycotope, MerckSerono, Merck/MSD, Pfizer; Research support: Pfizer, MerckSerono, Innate, Sirtec.
  • Khort Holbrook: No conflicts of interest to declare
  • Kinneally Ada: No conflicts of interest to declare
  • Kirby David: No conflicts of interest to declare
  • Koller Antje: No conflicts of interest to declare
  • Korenjak Marko: No disclosure at time of going online
  • Kornek Gabriella: No disclosure at time of going online
  • Kosmidis Paris: No conflicts of interest to declare
  • Labianca Roberto: Research grants – Roche, Sanofi
  • Lacointe-Artzner Estelle: No disclosure at time of going online
  • Ladetto Marco: No conflicts of interest to declare
  • Lawless Roisin: No conflicts of interest to declare
  • Lebrocquy Isabelle: No conflicts of interest to declare
  • Lewington Michelle: No conflicts of interest to declare
  • Licitra Lisa: Advisory Board: Bristol-Myers Squibb, GlaxoSmith Klein, Ely Lilly, Merck-Serono and Amgen; Institutional funds for clinical studies and research activities in which she is involved from EISAI, Exelixis, ly Lilly, Merck-Serono, Amgen; Travel coverages to attend medical meetings Merck-Serono.
  • Lindsell Sarah: No conflicts of interest to declare
  • Lordick Florian: Honoraria: Amgen, AstraZeneca, Astellas, Biontech, BMS, Eli Lilly, Elsevier, Excerpta Medica, Imedex, Infomedica, Iomedico, Medscape, MedUpdate, Merck Serono, MSD, Oncovis, Promedicis, Roche, Springer Nature, StreamedUp! and Zymeworks.
  • MacKay Pam: No disclosure at time of going online
  • Makaroff Lydia: Employee of the European Cancer Patient Coalition. The European Cancer Patient Coalition receives financial support from AbbVie, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Elly Lilly & Co, Genomic Health, Helsinn, Ipsen, Johnson & Johnson, LEO Pharma, Merck, MSD, Novartis, Pfizer, Roche, Takeda and Tesaro
  • Marchesi Vanessa: No conflicts of interest to declare
  • Margulies Anita: No conflicts of interest to declare
  • Martinelli Erika: Honoraria for lectures and advisory boards: Roche, Amgen, Servier and Sanofi
  • Mastris Ken: No conflicts of interest to declare
  • Metro Giulio: Honoraria from Anticancer Fund
  • Michiels Annemie: No conflicts of interest to declare
  • Mitsimponas Nikolaos: No conflicts of interest to declare
  • Moreau Philippe: Advisory Boards and Honoraria: Celgene, Janssen, Takeda, Amgen and Novartis.
  • Morement Helen: No disclosure at time of going online
  • Mussetti Alberto: No conflicts of interest to declare
  • Novello Silvia: Speaker’s bureau: Eli Lilly, Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Boehringer Ingelheim, Roche, Incyte, Takeda
  • Okines Alicia: Honorarium and travel support – Roche
  • Oliver Kathy: Honoraria for Healthcare Advisory Board (“HAB” – patient advocacy board) – GlaxoSmithKline; Honoraria for Global Council of the Patient Access to Cancer Care Excellence (PACE) initiative – Eli Lilly; Honoraria as a member of E-PALCO (European Cancer Patient Leaders Council) – Novartis; Honoraria for Worldwide Oncology Advocacy Advisory Board – Bristol-Myers Squibb; Honoraria for Advisory meeting – AbbVie; Honoraria for consultancy – Eli Lilly; Speaker fee: Bayer; Consultancy work EORTC/SPAEN Training Course in “Understanding Clinical Research”; Honoraria for consultancy work SPAEN training course in patient advocacy. KO is a Chair and Co-Director of the International Brain Tumour Alliance (IBTA) that accepted financial support and support in kind either directly or as part of a wider grouping of patient organisations from the following companies and trusts: Accuray, Antisense Pharma, Apogenix, Archimedes, Ark Therapeutics, Astra Zeneca, Boehringer Ingelheim, Brain Tumor Network (USA), Brain Tumor Resource and Information Network (USA), Bristol-Myers Squibb (BMS), Celldex Therapeutics, Crusade, Dijon Designs (UK), Elekta, Eli Lilly, Gerry & Nancy Pencer Brain Trust (Canada), Gosling Foundation (UK), GlaxoSmithKline (GSK), Ivy Foundation (USA), Lilly, Link Pharmaceuticals, Magforce, Medac, Merck Serono, Merck, MGI Pharma, MSD Oncology, NeoPharm, Neuroendoscopy (Australia), Northwest Biotherapeutics, Novartis, Novocure, Pediatric Brain Tumor Foundation (USA), Pfizer, Photonamic, Roche, Schering-Plough (Global), Sontag Foundation (USA), Spink (UK), to-BBB, Vane Percy (UK), VBL Therapeutics, Wallerstein Foundation (USA).
  • Pelouchova Jana: No disclosure at time of going online
  • Pentheroudakis George: Consulting and advisory services, speaking or writing engagements, public presentations: Amgen, Merck, AstraZeneca, Roche, BMS, MSD, Lilly; Direct research support: Boehringer, Merck, Amgen, AstraZeneca, Roche, Enorasis, BMS, Lilly; Institutional financial support for clinical trials or contracted research: Boehringer, Merck, Amgen, AstraZeneca, Roche, Lilly, Abbvie, Debiopharm, Ipsen
  • Peters Solange: Consultation / Advisory role (all fees to institution): Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics,Takeda and Vaccibody; Talk in a company’s organised public event (all fees to institution): AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Novartis, Pfizer, Sanofi, Takeda; Receipt of grants/research supports (all fees to institution): (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis, and Pfizer
  • Planchard David: Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Merck Sharp and Dohme Oncology, Novartis, Pfizer, prIME Oncology, Roche; Consulting, advisory role or lectures: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck Sharp and Dohme Oncology, Novartis, Pfizer, prIME Oncology, Roche; Travel grants: AstraZeneca, Roche, Novartis, prIME Oncology and Pfizer
  • Plataniotis George: No conflicts of interest to declare
  • Plate Ananda: No disclosure at time of going online
  • Polińska Agata: Honoraria: Bayer; Institutional financial interest - oncology health policy grant: MSD; Grants to Foundation for educational projects: Roche, Bayer, Gilead Science, Celgene, Janssen-Cilag, Novartis, Sanofi-Aventis, MagForce, Danone, Takeda, Pierre Fabre, Bristol Myers Squibb, Nutricia, AbbVie, Astellas Pharma, Servier Polska, MSD Polska, AstraZeneca, Boehringer-Ingelheim, Amgen
  • Provenzano Salvatore: No conflicts of interest to declare
  • Rapetti Simonetta: No disclosure at time of going online
  • Rauh Stefan: No conflicts of interest to declare
  • Rek Anna: Employee of the European Cancer Patient Coalition. The European Cancer Patient Coalition receives financial support from AbbVie, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Elly Lilly & Co, Genomic Health, Helsinn, Ipsen, Johnson & Johnson, LEO Pharma, Merck, MSD, Novartis, Pfizer, Roche, Takeda and Tesaro
  • Senkus Elzbieta: Receipt of grants/research support: Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, Pierre Fabre, Roche; Other support (travel expenses): Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, Novartis, Roche
  • Sessa Cristiana: No conflicts of interest to declare
  • Soo Ross: Honoraria: AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Ignyta, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, Yuhan; Direct research funding: AstraZeneca, Boehringer Ingelheim; Institutional financial interests: Abbvie, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Ignyta, Merck, Merck Serono, Novartis, Pfizer, Roche, Takeda, Yuhan
  • Spanic Tanja: Personal financial interest: Roche, AstraZeneca, Pfizer, Bayer
  • Spurrier Gilliosa: MelanomeFrance has received project funding from Roche, Novartis, BMS, Amgen - Support never includes editorial rights or influence on MelanomeFrance’s programme or activities; GS has received Patient Advocate Honoraria for Advisory boards from Amgen, BMS and Novartis
  • Stacchiotti Silvia: Research grants: Novartis, Pfizer, PharmaMar, GlaxoSmithKline, Amgen, Bayer
  • Stahl Michael: No conflicts of interest to declare
  • Stunt Ali: No disclosure at time of going online
  • Stupp Roger: Honoraria or consulting fee (paid to institution): Roche, Merck KGaA/EMD-Serono, MSD/Merck & Co, Pfizer, Ipsen Pharma, Novartis.
  • Sverre Hans: No disclosure at time of going online
  • Tanay Mary: No conflicts of interest to declare
  • Tassini Umberto: No conflicts of interest to declare
  • Ugarte Ana: No conflicts of interest to declare
  • Valle Juan: Honoraria/consultancy: Lilly, AstraZeneca and Sirtex; Rresearch support: Lilly, AstraZeneca and NuCana
  • Vallejo Ana: No disclosure at time of going online
  • Vallone Stefania: No conflicts of interest to declare
  • Van Cutsem Eric: Research funding – Amgen, MerckSerono, Phizer, Roche, Sanofi-Aventis
  • van Muilekom Erik: No disclosure at time of going online
  • Villa Giulia: No conflicts of interest to declare
  • Voitiekute Tanya: No disclosure at time of going online
  • Voiculescu Vlad: No conflicts of interest to declare
  • Vyas Malvika: No conflicts of interest to declare
  • Waldmann Anita: No conflicts of interest to declare
  • Wartenberg Markus: No disclosure at time of going online
  • Wilson Roger: No disclosure at time of going online
  • Zwinkels Hanneke: No conflicts of interest to declare

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings